Abstract Submission Guidelines
Abstracts submission portal
Our new submission portal officially opens on September 1, 2026. Please review the guidelines below to prepare your abstract.
-
Portal launch: September 1, 2026
-
Submission deadline: October 30, 2026, at 23:59 CET
We look forward to receiving your submissions!
Abstract structure
The abstract body should be structured under the following headings:
- Introduction/Background: Clearly state the objectives of the study.
- Methodology: Outline the study population, methods, and statistical considerations, where applicable.
- Results: Include definitive data (exempt for LBA placeholders).
- Conclusion: Clearly state the main findings and implications.
- Disclosures: List any relevant conflicts of interest (e.g., grant support, consultancy, advisory board membership, speaker bureau activities) over the past 3 years. This disclosure is mandatory for all authors.
- Acknowledgements: List any research grants, funding, or institutional financial support received for the study.
Presentation format
Authors can select one of the preferred presentation formats:
- Oral presentation
- Printed poster
- ePoster
- Video presentation
- Late-breaking abstract placeholder
- Poster for Patient Advocacy Seminar
The Scientific Programme Committee determines final presentation formats and session allocations based on peer-review scores.
Presenting authors under 40 years of age may apply for inclusion in the Young Investigator Sessions.
Authors are encouraged to provide comprehensive details to ensure reviewers have clear, thorough information for evaluation.
Instructions for abstract authors
- Submission format: Abstracts can only be submitted via the online form within set deadlines. Abstracts submitted by email will not be accepted.
- Language: Abstracts must be submitted in English, using UK English spelling.
- Submission lmits: ESGO Members can submit up to 3 abstracts while non-members only up to 2 abstracts.
- Title requirements: Authors must provide a short, specific title reflecting the scientific content. Maximum length: 50 words. Titles in ALL CAPS are not accepted. Please use sentence case (e.g., Efficacy of Treatment in Ovarian Cancer Patients).
- Word count limit: The abstract text may not exceed 300 words. This limit excludes the title, author list, disclosures, and acknowledgements.
- Author limits: The number of co-authors is strictly limited to 30 per abstract.
- Abbreviations: All abbreviations must be defined the first time they appear in the body text (abbreviations should not be used or defined in the title).
- Visual assets: A maximum of one table, figure, chart, or graphic may be included. It must be uploaded in high-resolution JPG format.
- Videos: Videos submitted for video sessions must not exceed 7 minutes in length, must be under 700 MB in size, and must be submitted in MP4 format.
- Late-breaking abstracts: A placeholder must be submitted by the regular abstract submission deadline. Abstracts submitted after this deadline will not be considered. Accepted LBAs not selected for oral presentation will be assigned as ePosters or may be rejected.
- Prior presentation: Abstracts should present work that has not been previously presented at another scientific meeting. Exceptions may be considered under the Encore Presentation category at the discretion of the Scientific Programme Committee.
- Prior publication: Abstracts reporting data already published in a peer-reviewed journal are not eligible for submission.
- Resubmissions: Abstracts previously presented at an ESGO Congress should not be resubmitted unless they contain substantial new data, analyses, or scientific findings.
- Multiple submissions: Submitting multiple abstracts derived from the same study, database, institution, or research programme is acceptable only when each abstract addresses a clearly distinct scientific question, analysis, endpoint, or hypothesis. The Scientific Programme Committee reserves the right to request consolidation of overlapping submissions.
- Commercial submissions: Abstracts submitted via commercial entities are welcome, provided they report collaborative research conducted by independent (non-commercial) investigators. Authors employed by commercial entities may be co-authors, but the presenting author must not be an employee of the sponsoring commercial company.
- Attendance policy: The presenting author of an accepted abstract must register for and attend the Congress by the early registration deadline (December 17, 2026).
- Final presentations: All authors are strongly encouraged to upload their final presentation files, videos, or ePosters via the portal prior to the Congress, eliminating the need for onsite uploads in the Speaker Ready Room.
We kindly ask you NOT to submit abstracts on following topics:
- Breast cancer
- Non-oncology related abstracts
- No single case reports unless accompanied by translational research or other wider research relating to the case
Once accepted for presentation, following information is applicable:
- Posters and/or ePosters can inlude QR codes with further information, narration or video.
- The copyright of all data belongs to authors who give permission to ESGO for publication in the IJGC and on eAcademy for registered users.
- The embargo for all abstracts end 10 days prior to the congress and on the first congress day in the case of LBA.
Abstract submission guidance on Diversity, Inclusion, and Representation
ESGO actively encourages researchers to promote diversity, equity, and inclusivity in the planning, conduct, and reporting of clinical studies.
-
Representation: Underrepresented populations should be appropriately represented whenever feasible to support equitable, comprehensive healthcare outcomes.
-
Demographic reporting: Authors are encouraged to report relevant demographic characteristics—including age, geographic region, ethnicity, and socioeconomic factors—using clear, respectful, and transparent definitions.
-
Generalisability: Authors should consider the applicability of their findings to real-world patient populations and justify major inclusion/exclusion criteria that may affect external validity.
-
Anonymity: To ensure an impartial peer-review process, do NOT refer to the institution or hospital where the research took place within the main text.
View the full recommendation here.
Selection process
- Double-blinded review: Abstracts will be reviewed in a double-blinded process by members of the Scientific Programme Committee, ESGO Council and Committee members, invited faculty, session chairs, and external experts, as appropriate.
- Late-breaking abstracts (LBA) review: The peer review of the completed, full data will be conducted by the Scientific Programme Committee shortly after the final LBA submission window closes.
- Presentation formats: The Scientific Programme Committee reserves the right to determine the final presentation format and session allocation based on peer-review scores. If several abstracts are based on related analyses of the same study or database, authors may be asked to consolidate the data into a single presentation.
- TransLink session: High-scoring abstracts in the Translational Research and Biomarkers topic area may be selected for oral presentation in the ESGO TransLink session.
- Results announcement: Review results will be announced on December 14, 2026 by notifying the submitting authors and publishing accepted abstract titles and presenting authors on the Congress website.
Explanation of submission categories & study design
Submission categories
- Standard Original Research: Completed original research presenting definitive data and analyses.
- First Presentation of Endpoint Analysis: Primary or secondary definitive endpoint data being disclosed for the first time.
- Late Breaking Abstracts (LBA) are reserved for newly emerging data that is not available by the regular abstract submission deadline. These could be the first presentation of study results or major analyses of key secondary endpoints. A placeholder LBA must be submitted containing the title, background, methods and a description of the type of results expected to be presented. Final LBA submissions will only be accepted if a placeholder abstract has been submitted during the regular abstract submission period. At the time of placeholder LBA submission, only the name of the first author needs to be provided (the full authorship list is required only at the time of final LBA submission). Placeholder abstracts will be evaluated during the review process and may be rejected prior to final data submission.
- Encore Abstracts: Encore submissions may be considered on an exceptional basis if the data have previously been presented at another scientific meeting, are of particular relevance to the ESGO audience, and have not been published in a peer-reviewed journal. Inclusion of updated analyses or additional data is strongly encouraged.
- Trials in progress (TiP): Ongoing studies for which definitive efficacy or outcome data are not yet available. TiP abstracts are eligible for poster or ePoster presentation only and are not eligible for oral presentation. TiP abstracts must not have been previously presented as a TiP at an ESGO Congress.
- Case reports for single cases will not be accepted unless they contain substantial translational work.
Study characteristics
- Randomised Controlled Trial (RCT): Interventional study in which participants are randomly assigned to one or more treatment groups and outcomes are compared between groups.
- Pragmatic Clinical Trial: Interventional study evaluating the effectiveness of healthcare interventions under routine clinical practice conditions.
- Prospective Observational Study: Observational study in which participants are followed forward in time and outcomes are collected according to a predefined protocol.
- Retrospective Study: Study based on previously collected data, medical records, databases, or registries.
- Single-Centre Study: Study conducted within a single institution or clinical centre.
- Multicentre Study: Study conducted across two or more institutions or clinical centres.
- Meta-analysis / Systematic Review: Study synthesising data from multiple published studies.
- Registry / Real-World Data Study: Observational study based on registry data, electronic health records, administrative databases, or other real-world data sources without investigator-assigned interventions.
Any Questions?
If you have questions regarding abstracts or need assistance, please contact:
Jakub Novak, Abstracts co-ordinator
E-mail: jakub.novak@esgo.org
Lenka Hovorkova, Scientific programme co-ordinator
E-mail: lenka.hovorkova@esgo.org
Tel: +420 607 990 671